Mode
Text Size
Log in / Sign up
N/A Completed N=16 Randomized Double-blind Treatment

Piloting "Signs of Safety": A Deaf-Accessible Therapy Toolkit for Alcohol Use Disorder and Trauma

Source: ClinicalTrials.gov NCT03845985 ↗
Enrolled (actual)
16
Serious AEs
0.0%
Results posted
Sep 2023
Primary outcomePrimary: Change From Baseline Percent Drinking Days Per Month at Immediate Post-Treatment — -20.00; -11.11 percent drinking days per month — p=.838

Summary

The U.S. Deaf community - more than 500,000 Americans who communicate using American Sign Language (ASL) - experiences nearly triple the rate of lifetime problem drinking and twice the rate of trauma exposure as compared to the general population. Although there are validated treatments for alcohol use disorder (AUD) and post-traumatic stress disorder (PTSD) in hearing populations, there are no evidence-based treatments for any behavioral health condition that have been validated for use with Deaf clients. To address these barriers, the study team has developed "Signs of Safety", a Deaf-accessible therapy toolkit for treating AUD and PTSD. The study team's ongoing aims are to conduct a two-arm pilot RCT of "Signs of Safety" and to collect data on feasibility, preliminary clinical outcomes, and potential mediators and moderators of outcome.

Outcome Measures

OutcomeResultp-value
PRIMARY
Change From Baseline Percent Drinking Days Per Month at Immediate Post-Treatment
-20.00; -11.11 .838
PRIMARY
Change From Baseline Percent Drinking Days Per Month at One-month Follow-up
-26.67; -13.33 .620
PRIMARY
Change From Baseline Percent Binge Drinking Days Per Month at Immediate Post-Treatment
17.78; -0.56 .713
PRIMARY
Change From Baseline Percent Binge Drinking Days Per Month at One-month Follow-up
-23.33; -0.67 .509
PRIMARY
Change From Baseline Number of Drinks Per Month at Immediate Post-Treatment
122.67; -9.17 .491
PRIMARY
Change From Baseline Number of Drinks Per Month at One-month Follow-up
-33.50; -22.90 .715
PRIMARY
Change From Baseline Past 30-day PTSD Severity to Immediate Post-Treatment as Assessed by PCL-5
-0.30; -0.53 .665
PRIMARY
Change From Baseline Past 30-day PTSD Severity at One-month Follow-up as Assessed by PCL-5
-0.40; -0.22 .875
SECONDARY
The Brief Comprehensive Effects of Alcohol Questionnaire (B-CEOA)
0.38; 0.05; -0.33; 0.00; 0.00; 0.00 .610
SECONDARY
Penn Alcohol Craving Scale (PACS)
1.33; -4.83 .407
SECONDARY
Trauma Symptom Checklist - 40 (TSC-40)
-0.22; -0.15 .893
SECONDARY
Behavior and Symptom Identification Scale - 24 (BASIS-24)
-0.16; .06 .709

Eligibility Criteria

Inclusion Criteria

  • Self-identification as a Deaf ASL user
  • Age 18 or older
  • Past-month alcohol consumption, as measured by the Alcohol Use Disorder Identification Test
  • Subthreshold or full PTSD on the PTSD Checklist for DSM-5 (past-month referent time period; "subthreshold" = endorsement of at least two B-E criteria at a severity of "moderate" or higher)
  • Ability to attend weekly study sessions at one of three study locations (Eastern, Central, or Western MA)
  • Ability to access a videophone (the standard telecommunication device for the Deaf community)

Exclusion Criteria

  • Participation in concurrent therapies (Note: Participants in both study conditions will be asked to refrain from concurrent formal psychotherapy; however, aligning with the Seeking Safety model, AA/NA/DRA attendance will be encouraged and attendance will be tracked as a potential outcome mediator).
  • Members of the following special populations: Adults unable to consent; Individuals younger than 18; Prisoners; Pregnant women (Note: We will not knowingly include pregnant women as participants; however, we will not assess participants' pregnancy status.)

Exclusion criteria are intentionally minimal to recruit a diverse sample. Other behavioral health comorbidities (e.g., mood/anxiety disorders, substance use disorders other than AUD) will not be excluded, given high rates of comorbidity.

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT03845985). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search